liquid biopsy

BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. It uses its proprietary Quantitative Counting Templates (QCTs) and single-molecule next-generation sequencing (smNGS) platform to directly measure sparse disease-causing DNA fragments at the single base-pair level, applying this technology to non-invasive prenatal screening and liquid biopsy.

cell-free DNA analysisclinical laboratory testingmolecular countingnon-invasive prenatal screeningsingle-molecule next-generation sequencing (smNGS)

BloodScan Biotech is a life science technology company pioneering a liquid biopsy platform based on circulating tumor cells (CTCs). Its flagship system, Labyrinth One, isolates intact and viable CTCs from a simple blood draw, delivering tissue-biopsy-equivalent insights non-invasively for cancer detection from stage 0 through advanced disease, treatment monitoring, and precision oncology research. The technology builds on over a decade of development and is validated by more than 15 peer-reviewed publications.

automated CTC isolationcell culturegenomicshistologylabel-free microfluidic CTC isolationproteomicssingle-cell sequencing

Captis Diagnostics develops extracellular vesicle (EV) isolation technology for minimally invasive human disease research and clinical diagnostics. Its Lipid Nanoprobe (LNP) platform enables rapid, high-efficiency EV isolation from human biofluids in 15 minutes or less without ultracentrifugation, supporting DNA mutation detection, RNA sequencing, and proteomics from a single blood draw. The company also offers precision EV isolation kits for multi-omics discovery and proteomics workflows.

DNA mutation detectionepigenomic profilingextracellular vesicle isolationmagnetic separationnext generation sequencingproteomicsRNA sequencing

The Istituto di Ricerca Genetica e Biomedica (IRGB) is a research institute of the Consiglio Nazionale delle Ricerche (CNR), with main offices in Monserrato (Cagliari) and secondary sites in Lanusei, Milan and Sassari. It conducts basic and translational research in genetics and biomedical genomics, including rare genetic diseases, cardiovascular diseases, regenerative medicine and oncology.

bioinformatics/high-performance computingcell biologycytogeneticsgenomicsgenotypingmolecular biologymolecular diagnosticsNGS sequencingproteomics

CorePath is a CLIA-certified and CAP-accredited laboratory headquartered in San Antonio, Texas, offering cancer diagnosis including morphologic evaluation, second opinion, immunohistochemistry, multicolor flow cytometry, cytogenetics, FISH, molecular genetics, next generation sequencing and liquid biopsy testing. Its team of Board Certified Pathologists and clinical lab scientists provides diagnosis for cancer patients in the United States and worldwide.

biomarkers analysisclinical trialscytogeneticsFISHhistologyimmunohistochemistrymulticolor flow cytometrynew test and platform validationnext generation sequencingtissue banking

CpG Diagnostics is a diagnostics company founded to transform cancer diagnostics through epigenetic technology, beginning with ovarian cancer. It is developing OvaPrint, a methylation-based blood test using AI-powered analysis to distinguish malignant from benign adnexal masses and support ovarian cancer diagnosis.

AI-powered analysisclinical validation studiesmethylation-based diagnostics

Definitive Diagnostics develops an AI-enabled, protein-based blood test platform for earlier cancer detection. Its patented method measures 16 abundant protein/immune biomarkers forming cancer-specific patterns, designed to reduce false positives and unnecessary procedures. The company reports independent validation of 99% sensitivity (Stage 0 breast), 97% specificity, and 98% Tissue of Origin, and has detected cancer as early as Stage 0 in breast and Stage I in lung, colorectal, ovarian, and pancreatic cancers.

AI-supported detectionbiomarker measurementprotein pattern recognitionTissue of Origin determination

Enumera Molecular is a clinical diagnostics company developing the EnumeraPlex single-molecule counting platform, a proprietary technology designed to simplify complex, high-analyte molecular testing in a lab-friendly format. Its pan-omic detection covers genomic, epinomic, transcriptomic, and proteomic analysis with no PCR bias and bioinformatics-free analysis, aimed at democratizing liquid biopsy and clinical omics for labs of all sizes.

amplificationautomated data analysishybridizationimaginglabelingnucleic acid preparationpan-omic analysissample-to-answer workflowsingle-molecule counting

Eurofins Transplant Genomics is committed to improving organ transplant outcomes with noninvasive diagnostics guided by genetic biomarkers. It develops molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes, and enable optimization of therapy for kidney and liver transplant recipients.

donor-derived cell-free DNA (dd-cfDNA) testinggene expression profilingmolecular diagnosticsnoninvasive rejection monitoring

Exai Bio is a next-generation liquid biopsy company using a novel RNA-based platform with oncRNA biomarkers and AI to deliver actionable insight into cancer biology from a simple blood draw. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, managed precisely, and ultimately cured. The oncRNA technology began in the laboratories of the University of California, San Francisco.

Artificial intelligenceRNA biomarker discovery

FYR Bio is a precision medicine company whose EV-Omics (EVO) platform uses AI-enabled multi-omic insights to profile extracellular vesicles (EVs) in blood, decoding RNA and protein signals to support biomarkers, clinical trials, diagnostics, and drug development. Its proprietary SPARCs technology enriches disease-associated EVs to improve signal-to-noise. The company partners on study design, custom data outputs, and clinical validation across diagnostics, drug development, and precision medicine.

AI-enabled multi-omic insightsbiomarker discoveryCLIA laboratory testingclinical validationextracellular vesicle profilingRNA and protein analysis